<i>N</i>-(ω-(4-(2-Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as Dopamine D<sub>2</sub> and D<sub>3</sub> Receptor Ligands
Anneke E. Hackling(Goethe University Frankfurt), Holger Stark(Heinrich Heine University Düsseldorf), Wolfgang Sippl(Paradise Valley Community College), Sylvie Perachon(Goethe University Frankfurt), Jean‐Charles Schwartz(Inserm), André Mann(Goethe University Frankfurt), Camille G. Wermuth(Goethe University Frankfurt), Robin Ghosh(Goethe University Frankfurt), Hans‐Dieter Höltje(Goethe University Frankfurt), Pierre Sokoloff(Inserm)
Cited by 104
Related Papers
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
|Pharmacological Reviews|2015|558
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
|Journal of Medicinal Chemistry|2018|476
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
|Nature Medicine|2003|381
DOGS: Reaction-Driven de novo Design of Bioactive Compounds
|PLoS Computational Biology|2012|264
Neurochemical and Behavioral Effects of Ciproxifan, A Potent Histamine H3-Receptor Antagonist
|Journal of Pharmacology and Experimental Therapeutics|1998|240